Get started now with business coaching
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Latest content
Israel Cancer Research Fund Impact Statement 2022
2022 has been a mixed year for all of us. On the one hand, we have seen a return to in-person activities and are slowly able to reestablish our pre-COVID…
Switching Between Intravenous and Oral P2Y12 Inhibition: Easier Said Than Done
Adequate suppression of platelet reactivity is necessary to mitigate early thrombotic events, including stent thrombosis, among patient undergoing percutaneous coronary intervention (PCI). Clinical trials conducted more than 20 years ago established…
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet
Abstract Background There are no studies specifically designed to rule out a drug-drug interaction (DDI) when cangrelor is used among patients who have been pretreated with ticagrelor. Objectives This study sought to rule…
Researchers Will Train AI to Diagnose Prostate Cancer
Himanshu Arora, Ph.D., oncology and urology researcher at Sylvester Comprehensive Cancer Center and Desai Sethi Urology Institute, both part of the University of Miami Miller School of Medicine, has received a $78,000 grant from…
New Strategies For Tackling Triple-Negative Breast Cancer
Research at JAX has uncovered a molecular “fingerprint” that could lead to better outcomes for TNBC patients. JAX Associate Research Scientist Francesca Menghi wants oncologists to have a much larger…
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes
Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Maryuri…
Having problems? need help with your account?
Support hours are M-F
10am-7pm (Los Angeles)